Mukesh Harisinghani, MD
Associate Professor of Radiology, Harvard Medical School
Assistant Radiologist, Dept. of Abdominal Imaging
Phone: 617-726-8396
Email: mharisinghani@mgh.harvard.edu
Design and conduct clinical trials and provide an avenue for clinical testing of novel imaging agents developed at CMIR.
Over the last several years we have conducted phase 1,2 and phase 3 clinical trials of monocrystalline iron oxides (1-2) for a number of applications. Current trials evaluate the efficacy of these agents to improve detection of subtle lymph node metastases in patients with prostate cancer (funded in part by RSNA) and renal cancer (funded in part by by SCBT).
My primary clinical interests lie in abdominal and pelvic MR imaging
Publications
Kaufman DS, McDougal WS, Harisinghani MG, Wu CL
Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.
New Engl J Med. 2009;361(13):1292-9 - PMID: 19776411
Macdonald SM, Harisinghani MG, Katkar A, Napolitano B, Wolfgang J, Taghian AG
Nanoparticle-Enhanced MRI to Evaluate Radiation Delivery to the Regional Lymphatics for Patients With Breast Cancer.
Int J Radiat Oncol Biol Phys. 2009;:ePub - PMID: 19836160
Pandharipande PV, Mora JT, Uppot RN, Goehler A, Braschi M, Halpern EF, Gazelle GS, Harisinghani MG
Lymphotropic nanoparticle-enhanced MRI for independent prediction of lymph node malignancy: a logistic regression model.
Am J Roentgenol. 2009;193(3):W230-7 - PMID: 19696264
Baier ND, Hahn PF, Gervais DA, Samir A, Halpern EF, Mueller PR, Harisinghani MG
Fine-needle aspiration biopsy of thyroid nodules: experience in a cohort of 944 patients.
Am J Roentgenol. 2009;193(4):1175-9 - PMID: 19770344
Gee MS, Harisinghani MG, Tabatabaei S
Molecular imaging in urologic surgery.
Urol Clin N Am. 2009;36(2):125-32 - PMID: 19406314
Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M
Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.
Clin Imag. 2009;33(4):301-5 - PMID: 19559353
Islam T, Harisinghani MG
Overview of nanoparticle use in cancer imaging.
Cancer Biomark. 2009;5:61-7 - PMID: 19414922
Harisinghani MG
Nanoparticle enhanced imaging.
8
Harisinghani M
Nanoparticle-enhanced MRI: are we there yet?
Lancet Oncol. 2008;9(9):814-815 - PMID: 18760237
Feldman AS, McDougal WS, Harisinghani MG
The potential of nanoparticle-enhanced imaging.
Urol Oncol. 2008;26(1):65-73 - PMID: 18190834
Pandharipande PV, Harisinghani MG, Ozanne EM, Specht MC, Hur C, Lee JM, Gazelle GS
Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis.
Am J Roentgenol. 2008;191:1308-19 - PMID: 18941062
Guimaraes AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG
Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer.
Urology. 2008;71(4):708-12 - PMID: 18295316
Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR
Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Ann Thorac Surg. 2008;86:1131-8 - PMID: 18805147
Li CS, Harisinghani MG, Lin WC, Braschi M, Hahn PF, Mueller PR
Enhancement Characteristics of Ultrasmall Superparamagnetic Iron Oxide Particle Within the Prostate Gland in Patients With Primary Prostate Cancer.
J Comput Assist Tomo. 2008;32:523-528 - PMID: 18664836
Roedl JB, Blake MA, Holalkere NS, Mueller PR, Colen RR, Harisinghani MG
Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters.
Abdom Imaging. 2008;:ePub - PMID: 18830663
7
Harisinghani M, Ross R, Guimaraes A, Weissleder R
Utility of a New Bolus-Injectable Nanoparticle for Clinical Cancer Staging
1
Saksena M, Harisinghani M, Hahn P, Kim J, Saokar A, King B, Weissleder R
Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers.
Am J Roentgenol. 2006;187(6):W582-8 - PMID: 17114509
Harisinghani MG, Saksena MA, Hahn PF, King B, Kim J, Torabi MT, Weissleder R
Ferumoxtran-10-Enhanced MR Lymphangiography: Does Contrast-Enhanced Imaging Alone Suffice for Accurate Lymph Node Characterization?
Am J Roentgenol. 2006;186(1):144-8 - PMID: 16357394
Saksena MA, Saokar A, Harisinghani MG
Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging.
Eur J Radiol. 2006;58(3):367-74 - PMID: 16472955
Ross R, Harisinghani M
Prostate cancer imaging-what the urologic oncologist needs to know.
Radiol Clin N Am. 2006;44(5):711-22 - PMID: 17030222
Ross R, Harisinghani M
New clinical imaging modalities in prostate cancer.
Hematol Oncol Clin N. 2006;20(4):811-30 - PMID: 16861116
Saokar A, Braschi M, Harisinghani M
Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging.
Abdom Imaging. 2006;:ePub - PMID: 16680506
6
Shih HA, Harisinghani M, Zietman AL, Wolfgang JA, Saksena M, Weissleder R.
Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy
Int J Radiat Oncol Biol Phys. 2005;63(4):1262-9 - PMID: 16253781
Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, Weissleder R
A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation.
Urology. 2005;66(5):1066-71 - PMID: 16286125
2
Harisinghani MG, Weissleder R
Sensitive, noninvasive detection of lymph node metastases.
1
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
New Engl J Med. 2003;348:2491-9 - PMID: 12815134
1
Harisinghani MG, Barentsz JO, Hahn PF, Deserno W, de la Rosette J, Saini S, Marten K, Weissleder R
MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer
Acad Radiol. 2002;9 Suppl 2:S312-3 - PMID: 12188258
1
Harisinghani MG, Saini S, Weissleder R, Rubin D, deLange E, Harms S, Weinreb J, Small W, Sukerkar A, Brown JJ, Zelch J, Lucas M, Morris M, Hahn PF
Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations
J Comput Assist Tomo. 2001;25:770-6 - PMID: 11584239
Harisinghani MG, Jhaveri KS, Weissleder R, Schima W, Saini S, Hahn PF, Mueller PR
MRI contrast agents for evaluating focal hepatic lesions
Clin Radiol. 2001;56:714-25 - PMID: 11585393
2
Harisinghani MG, Saini S, Weissleder R, Hahn PF, Yantiss RK, Tempany C, Wood BJ, Mueller PR
MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation
Am J Roentgenol. 1999;172:1347-51 - PMID: 10227514
Schima W, Saini S, Petersein J, Weissleder R, Harisinghani M, Mayo-Smith W, Hahn PF
MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses
J Magn Reson Imaging. 1999;10:80-3 - PMID: 10398981
2
|
